









Markets
/
Stocks
/
nasdaq-gbio
/

Generation Bio Co

GBIO

5.750USD

-0.230-3.85%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

3.87MMarket Cap

LossP/E TTM



Generation Bio Co

5.750

-0.230-3.85%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a good stock market performance and strong technicals, the fundamentals don't support the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

148 / 506

Overall Ranking

257 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 6 analysts

Buy

Current Rating

26.750

Target Price

+347.32%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Generation Bio Co. is a biotechnology company. The Company is innovating non-viral genetic medicines to provide durable, redosable treatments for hundreds of millions of patients living with rare and prevalent diseases. The Company is developing two distinct and complementary platforms: a potent, highly selective cell-targeted lipid nanoparticle (ctLNP) delivery system and a novel immune-quiet DNA (iqDNA) cargo produced by a scalable capsid-free manufacturing process that uses proprietary cell-free rapid enzymatic synthesis (RES). The Company is advancing a portfolio of programs guided by the potent and highly selective delivery of messenger ribonucleic acid (mRNA) and/or iqDNA using its ctLNP delivery system to target T cells, hematopoietic stem cells (HSCs), and hepatocytes, and intend to expand to additional tissues and cell types. Its work in T cells focuses on in vivo reprogramming of this cell type to treat cancer and autoimmune diseases.

Growing

The company is in a growing phase, with the latest annual income totaling USD 19.89M.

Overvalued

The company’s latest PE is -0.11, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 5.68M shares, decreasing 24.75% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 829.98K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.56.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 5.60, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 765.00K, representing a year-over-year decrease of 81.30%, while its net profit experienced a year-over-year decrease of 2.40%.

Score

Industry at a Glance

Previous score

5.60

Change



Financials

5.69

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.37

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.77

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

5.09

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.09

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -0.11, which is -0.90% below the recent high of -0.11 and -218.00% above the recent low of -0.35.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 148/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 7.33, which is lower than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Generation Bio Co is 13.50, with a high of 70.00 and a low of 10.00.

Score

Industry at a Glance

Previous score

7.33

Change

Support & Resistance

No Data

Analyst Rating

Based on 6 analysts

Buy

Current Rating

26.750

Target Price

+347.32%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Generation Bio Co

GBIO

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 6.86, which is higher than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 6.52 and the support level at 5.48, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.86

Change

-0.36

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(4)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.277

Neutral

RSI(14)

52.627

Neutral

STOCH(KDJ)(9,3,3)

42.134

Neutral

ATR(14)

0.322

High Vlolatility

CCI(14)

-46.252

Neutral

Williams %R

67.568

Sell

TRIX(12,20)

0.499

Sell

StochRSI(14)

21.197

Sell

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

5.808

Sell

MA10

5.894

Sell

MA20

5.994

Sell

MA50

4.752

Buy

MA100

2.565

Buy

MA200

1.655

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 7.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 84.67%, representing a quarter-over-quarter decrease of 2.96%. The largest institutional shareholder is PRFDX, holding a total of 829.98K shares, representing 12.32% of shares outstanding, with 9.53% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

T. Rowe Price Associates, Inc.

Star Investors

8.88M

-2.39%

Atlas Venture

8.28M

Modernatx Inc

5.86M

Invus Public Equities Advisors, LLC

2.97M

-0.46%

Renaissance Technologies LLC

Star Investors

1.88M

+95.30%

Fidelity Management & Research Company LLC

4.75M

+2.73%

The Vanguard Group, Inc.

Star Investors

2.62M

-0.84%

Baker Bros. Advisors LP

1.94M

McDonough (Cameron Geoffrey)

1.85M

+0.83%

Acadian Asset Management LLC

1.16M

+54.29%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 2.98, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 2.54. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.